Compare ResMed Inc. (RMD) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Sunrun Inc — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.78B), while Sunrun Inc trades at $7.68 (market cap $1.83B). The key difference: ResMed Inc. is far larger — about 17.4× Sunrun Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Sunrun Inc for 16 Days on average.
| RMD | RUN | |
|---|---|---|
Market Cap | $31.78B | $1.83B |
Volume | 1,128,382 | 13,379,830 |
Sector | Health | Energy |
52-Week High | $277.88 | $21.41 |
52-Week Low | $182.82 | $7.59 |
Typical Hold Time | 51 Days | 16 Days |
Enterprise Value | $31.14B | $16.35B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Sunrun (RUN) trades at $7.61, down 2.06% amid broader solar sector weakness. The stock shows bearish technical signals with oversold RSI levels, while fundamentals reveal strong earnings beats but negative operating cash flow. Recent partnerships with Tesla and Voltus highlight growth potential in distributed energy, though high borrowing costs pressure project financing.
Wall Street maintains a bullish consensus with a $16.56 price target (62% buy ratings), but risks include persistent cash burn, interest expense burden, and solar industry headwinds. The stock trades at discounted valuations (P/E 5.18, P/B 0.53) but requires improved profitability to justify analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
